Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.36 |
| ▸ | KIF18A | Q8NI77 | 4/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 3/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5723758 | 0.91 | OPRK1 (0.42) | OPRK1TGFBR1PTPN1KIF18AKDM1A | |
| SCHEMBL4017796 | 0.87 | OPRK1 (0.43) | OPRK1TGFBR1PTPN1KDM1ARXRA | |
| SCHEMBL4381622 | 0.74 | OPRK1 (0.47) | OPRK1 | |
| SCHEMBL4019776 | 0.68 | OPRM1 (0.46) | OPRK1 | |
| SCHEMBL4019150 | 0.67 | OPRK1 (0.41) | OPRK1SIGMAR1 | |
| SCHEMBL4023569 | 0.66 | OPRM1 (0.45) | OPRK1 | |
| SCHEMBL4019941 | 0.65 | OPRM1 (0.55) | OPRK1SIGMAR1 | |
| SCHEMBL4019499 | 0.65 | CHRM3 (0.41) | OPRK1 | |
| SCHEMBL29728634 | 0.65 | ESR2 (0.56) | PTPN1NR1H2 | |
| SCHEMBL16645224 | 0.65 | ESR2 (0.56) | PTPN1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615893-B1 | 2-AZABICYCLO¬3.3.1 NONANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-RE40838-E1 | 2-azabicyclo[3.3.1]nonane derivatives | PFIZER INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7056930-B2 | for treatment of disease states, disorders and conditions mediated by opioid receptors; for example, irritable bowel syndrome, drug addiction, including alcohol addiction, depression, anxiety, schizophrenia, eating disorders | PFIZER INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1615893-A1 | 2-AZABICYCLO[3.3.1]NONANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089909-A1 | 2-AZABICYCLO[3.3.1]NONANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204445-A1 | 2-Azabicyclo[3.3.1]nonane derivatives | PFIZER INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204445-A1 | 2-Azabicyclo[3.3.1]nonane derivatives | OPRD1, OPRK1, OPRM1 | OPRK1 2/4885TGFBR1 706/4885PTPN1 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.